# A Translational Roadmap for Neurological Nonsense Mutation Disorders

## TL;DR

This paper outlines a new strategy to treat neurological diseases caused by genetic errors that stop protein production.

## Contribution

The paper introduces a structured translational framework called the '4 Ds of Readthrough Therapy' to improve treatment of nonsense mutation disorders.

## Key findings

- Readthrough therapies have advanced but face challenges in CNS delivery and efficacy.
- The proposed framework includes Detection, Delivery, Decoding, and Durability to guide treatment development.
- Integration of machine learning and nanocarriers could enable precision-based cures for neurological disorders.

## Abstract

Nonsense mutations, responsible for ~11% of gene lesions causing human monogenic diseases, introduce premature termination codons (PTCs) that lead to truncated proteins and nonsense-mediated mRNA decay (NMD). In the central nervous system (CNS), these mutations drive severe, progressive neurological conditions such as spinal muscular atrophy, Rett syndrome, and Duchenne muscular dystrophy. Readthrough therapies—strategies to override PTCs and restore full-length protein expression—have evolved from early aminoglycosides to modern precision tools including suppressor tRNAs, RNA editing, and CRISPR-based platforms. Yet clinical translation remains hampered by inefficient CNS delivery, variable efficacy, and the absence of personalized stratification. In this review, we propose a translational framework—the 4 Ds of Readthrough Therapy—to systematically address these barriers. The framework dissects the pipeline into Detection (precision patient identification and biomarker profiling), Delivery (engineered vectors for CNS targeting), Decoding (context-aware molecular correction), and Durability (long-term safety and efficacy). By integrating advances in machine learning, nanocarriers, base editing, and adaptive trial designs, this roadmap provides a structured strategy to bridge the translational gap. We advocate that a synergistic, modality-tailored approach will transform nonsense suppression from palliative care to durable, precision-based cures for once-untreatable neurological disorders.